Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook


DNDi Strategy for VL


Short term
: Better use of existing treatments through geographical extension and new combinations
  • Combination in Africa: Registration of paromomycin in 2010, recommendation of combination including paromomycin + sodium, stibogluconate (SSG), registration of AmBisome® in 2011, registration of miltefosine, development of combination with short-course AmBisome®
  • Combination in India: Recommendation in India, Bangladesh and Nepal by 2011
  • Combination in Latin America: Recommendation in 2013

Medium term: Registration of one new drug through new formulations of existing treatments and therapeutic switching
  • Alternative formulations of amphotericin B – DNDi is evaluating an oral formulation developed by BioDelivery Sciences International (BDSI)
  • 8-aminoquinolines – DNDi is in discussion with GlaxoSmithKline (GSK) about tafenoquine and sitamaquine for clinical development
  • Potential compounds in-sourced at late preclinical phase – DNDi is actively pursuing potential candidates ready for clinical development in the short term
Long term: New compounds and improved research capacity
  • New drugs developed from compounds identified (i.e. 2-quinolines) in discovery research and progressed through VL lead optimisation consortium
  • Multi-country, multi-partner LEAP to strengthen regional research capacity

By 2014, DNDi aims to deliver from its VL-specific portfolio:
  • 1 new drug registered
  • 1-3 geographical extensions in endemic regions outside India by 2014
  • 1-3 coadministrations recommended by WHO
  • A robust pipeline

Madrid Statement on Visceral Leishmaniasis Therapy (July 15, 2009)

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License